These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 31433337)
21. Olanzapine: a review of rapid and long-acting parenteral formulations. Owen RT Drugs Today (Barc); 2010 Mar; 46(3):173-81. PubMed ID: 20467591 [TBL] [Abstract][Full Text] [Related]
22. Olanzapine long-acting injection: a review of first experiences of post-injection delirium/sedation syndrome in routine clinical practice. Bushe CJ; Falk D; Anand E; Casillas M; Perrin E; Chhabra-Khanna R; Detke HC BMC Psychiatry; 2015 Apr; 15():65. PubMed ID: 25886006 [TBL] [Abstract][Full Text] [Related]
23. Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a second-generation antipsychotic. Citrome L Int J Clin Pract; 2009 Jan; 63(1):140-50. PubMed ID: 18834452 [TBL] [Abstract][Full Text] [Related]
24. Drug safety evaluation of olanzapine pamoate. Schöttle D; Kuhnigk O; Naber D Expert Opin Drug Saf; 2013 Nov; 12(6):897-903. PubMed ID: 24024627 [TBL] [Abstract][Full Text] [Related]
25. Olanzapine pamoate for the treatment of schizophrenia. Naber D Expert Opin Pharmacother; 2011 Mar; 12(4):627-33. PubMed ID: 21254860 [TBL] [Abstract][Full Text] [Related]
26. A Case of Olanzapine-Induced Fever. Yang CH; Chen YY Psychopharmacol Bull; 2017 Jan; 47(1):45-47. PubMed ID: 28138204 [TBL] [Abstract][Full Text] [Related]
27. Benefit of extending the dosing interval of olanzapine on schizophrenics during maintenance treatment. Suzuki H; Hibino H; Inoue Y; Mikami A; Matsumoto H; Mikami K Asian J Psychiatr; 2017 Dec; 30():100-101. PubMed ID: 28858761 [No Abstract] [Full Text] [Related]
28. Olanzapine-induced and Risperidone-induced Leukopenia: A Case of Synergistic Adverse Reaction? Woon LS; Tee CK; Gan LLY; Deang KT; Chan LF J Psychiatr Pract; 2018 Mar; 24(2):121-124. PubMed ID: 29509183 [TBL] [Abstract][Full Text] [Related]
29. Delirium with dystonia: a variant of neuroleptic malignant syndrome? Dowling JJ; Patrick V Am J Psychiatry; 1989 Feb; 146(2):276-7. PubMed ID: 2563212 [No Abstract] [Full Text] [Related]
30. Olanzapine pamoate for the treatment of schizophrenia--a safety evaluation. Samalin L; Garay R; Ameg A; Llorca PM Expert Opin Drug Saf; 2016; 15(3):403-11. PubMed ID: 26761429 [TBL] [Abstract][Full Text] [Related]
31. Baseline characteristics and hospitalizations in patients with schizophrenia receiving olanzapine long-acting injection: an interim analysis from a non-interventional, prospective observational safety study. Jones ME; Andrews JS; Faries DE; Landry J; Xu J; Detke HC; Chhabra-Khanna R; McDonnell DP BMC Psychiatry; 2015 Nov; 15():278. PubMed ID: 26567159 [TBL] [Abstract][Full Text] [Related]
32. Acute Necrotizing Pancreatitis Associated With Orally Disintegrating Formulation of Olanzapine: Implications on Clinical Presentation and Management. Vaidyanathan S; Subramanian K; Bharadwaj B; Das S; Kola GST; Maroju NK J Clin Psychopharmacol; 2019; 39(5):519-521. PubMed ID: 31433336 [No Abstract] [Full Text] [Related]